15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Uipath Inc, 2 rate it Buy or better, 11 sit at Hold, and 1 rate it Sell or worse, a hold consensus. Targets span $12.00 to $18.00, a moderate spread. The average target of $14.07 sits 16% above the current $12.18. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.19 next quarter toward $0.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Hold
Strong Buy00%
Buy214%
Hold1179%
Sell17%
Strong Sell00%
Based on 14 analysts giving stock ratings to Uipath Inc.
As of Jul, 2 of 14 firms rate PATH a Buy (11 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PATH EPS & revenue forecast
EPS · NEXT QUARTER
$0.19
Range $0.16 – $0.21 · 19 analysts · +17% YoY
Next period, 19 analysts expect Uipath Inc to earn $0.19 a share (range $0.16 – $0.21), versus $0.16 a year earlier. Full-year consensus is $0.79, growing to $0.91 the year after.
REVENUE · NEXT QUARTER
$441.2M
Range $429.0M – $447.8M · 19 analysts · +7% YoY
Revenue is expected to reach $441.2M (range $429.0M – $447.8M), +7.3% year-over-year. Full-year consensus is $1.8B, rising to $1.9B next year.
Top analysts covering Uipath Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PATH.
#1
Raimo Lenschow
Barclays · Rank #285
Hold
$14.00+15.0% to target
Overall win rate
37%
+ Follow
#2
Scott Berg
Needham · Rank #388
Buy
$15.00+23.2% to target
Overall win rate
18%
+ Follow
#3
Keith Bachman
BMO Capital
Hold
$13.00+6.8% to target
Coverage
—
+ Follow
#4
KC
Kingsley Crane
Canaccord Genuity
Buy
$15.00+23.2% to target
Coverage
—
+ Follow
#5
LS
Lucky Schreiner
DA Davidson
Hold
$12.00-1.4% to target
Coverage
—
+ Follow
PATH stock forecast FAQ
What is PATH's average 12-month price target?+
The 14 analysts with a live target average $14.07 for Uipath Inc over the next 12 months, ranging from a $18.00 high to a $12.00 low.
Is PATH stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 14 analyst ratings, 2 are Buy or Strong Buy, 11 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for PATH?+
The Street-high target is $18.00 (Barclays), and the Street-low is $12.00 (UBS). The average of all 14 active targets is $14.07.
How many Wall Street analysts cover PATH?+
14 analysts have an active rating on Uipath Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering PATH?+
Among analysts who currently cover PATH, Raimo Lenschow of Barclays has the strongest overall Quantellect track record (Rank #285). Their current call is Hold with a $14.00 target.
What is Uipath Inc's projected EPS for next quarter?+
The consensus estimate is $0.19 per share (range $0.16 – $0.21) across 19 analysts. Full-year EPS is projected at $0.79, rising to $0.91 the following year.
How much revenue is Uipath Inc expected to report next quarter?+
Consensus revenue is $441.2M (range $429.0M – $447.8M). Full-year revenue is projected at $1.8B, growing to $1.9B next year.
Have analysts been upgrading or downgrading PATH lately?+
As of Jul, 2 of 14 firms rate PATH a Buy (11 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PATH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
